Otonomy, Inc.

Quick facts

Phase 3 pipeline

• OTO-201 · Otology/Ear, Nose, and Throat
  OTO-201 is a sustained-release corticosteroid formulation designed to deliver dexamethasone directly into the middle ear to reduce inflammation and fluid accumulation.
• OTO-201 (ciprofloxacin) · Otology / Infectious Disease
  OTO-201 is a sustained-release formulation of ciprofloxacin, a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV to kill bacteria in the middle ear.

Phase 2 pipeline

• OTO-313

Phase 1 pipeline

• OTO-413

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Otonomy, Inc. portfolio CI brief
• Otonomy, Inc. pipeline updates RSS